Ngā hua rapu - Marc Ditmarsch

  • E whakaatu ana i te 1 - 8 hua o te 8
Whakamahine hua
  1. 1
    Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

    Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? mā Nick S. Nurmohamed, Marc Ditmarsch, John J.P. Kastelein

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments

    Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments mā John J.P. Kastelein, Andrew Hsieh, Mary R. Dicklin, Marc Ditmarsch, Michael H. Davidson

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

    Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial mā Stephen J. Nicholls, Marc Ditmarsch, John J.P. Kastelein, Scott P. Rigby, Douglas Kling, Danielle Curcio, Nicholas John, Michael H. Davidson

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

    Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels mā Adam J. Nelson, Allan D. Sniderman, Marc Ditmarsch, Mary R. Dicklin, Stephen J. Nicholls, Michael H. Davidson, John J.P. Kastelein

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

    Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial mā Christie M. Ballantyne, Marc Ditmarsch, John J.P. Kastelein, Adam J. Nelson, Douglas Kling, Andrew Hsieh, Danielle Curcio, Kevin C. Maki, Michael H. Davidson, Stephen J. Nicholls

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

    Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial mā Mariko Harada‐Shiba, Michael H. Davdison, Marc Ditmarsch, Andrew Hsieh, Erin Wuerdeman, Douglas Kling, A. Nield, Mary R. Dicklin, Akitaka Nakata, Atsushi Sueyoshi, Satoshi Kuroyanagi, John J.P. Kastelein

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

    The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial mā Kausik K. Ray, Marc Ditmarsch, David Kallend, Eric J. Niesor, Gabriela Suchánková, Ruchi Upmanyu, Judith Anzures‐Cabrera, Valerie Lehnert, Meike Pauly-Evers, Ingar Holme, Josef Šťásek, M. W. J. van Hessen, Peter J.H. Jones

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN

    Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADW... mā Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J.P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Návar, Steven E. Nissen, Anne C. Golberg, Liam R. Brunham, Danielle Curcio, Erin Wuerdeman, Annie Neild, Douglas Kling, Andrew Hsieh, Mary R. Dicklin, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael H. Davidson

    I whakaputaina 2024
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: